Li Wang has extensive experience in the biostatistics and statistical innovation fields, having held significant positions at AbbVie and Bristol-Myers Squibb. At AbbVie, Li served as the Head of Statistical Innovation, where responsibilities included managing teams and leading critical AI/ML initiatives for Clinical Development. Prior roles at AbbVie involved directing predictive analytics efforts and overseeing compound development in immunology. Li's tenure at Bristol-Myers Squibb featured pivotal contributions as a Principal Biostatistician for key drug approvals, including Eliquis and Onglyza. Academic achievements include a PhD in Statistics from Virginia Tech and an Executive MBA from Northwestern University's Kellogg School of Management.
This person is not in any teams
This person is not in any offices